

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

MM1.S

RRID:CVCL_8792

Type: Cell Line

Proper Citation

RRID:CVCL_8792

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8792

Proper Citation: RRID:CVCL_8792

Description: Cell line MM1.S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:12691914](#), [PMID:14760100](#), [PMID:16956823](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Sensitive to dexamethasone., Characteristics: Produces IgA lambda (ATCC=CRL-2974)., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MM1.S

Synonyms: MM.1S, MM1-S, MM-1S, MM1S

Cross References: BTO:BTO_0003933, CLO:CLO_0037203, EFO:EFO_0005724, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, ATCC:CRL-2974, BioGRID_ORCS_Cell_line:801, BioSample:SAMN03471684, BioSample:SAMN10988254, cancercellines:CVCL_8792,

CCRID:1101HUM-PUMC000680, CCRID:3101HUMSCSP5017,
Cell_Model_Passport:SIDM01265, ChEMBL-Cells:ChEMBL4295490, ChEMBL-
Targets:ChEMBL4296471, CLS:305304, Cosmic:1424218, Cosmic:1483077,
Cosmic:1762460, Cosmic:1889512, Cosmic:2081430, Cosmic:2391805, Cosmic:2809756,
Cosmic-CLP:1659818, DepMap:ACH-000763, EGA:EGAS00001000610,
EGA:EGAS00001000978, ENCODE:ENCBS205VYW, ENCODE:ENCBS241TLI,
ENCODE:ENCBS299YQN, ENCODE:ENCBS523NFL, ENCODE:ENCBS981ZAE,
GDSC:1659818, GEO:GSM562814, GEO:GSM887328, GEO:GSM888404,
GEO:GSM1374685, GEO:GSM1666388, GEO:GSM1670118, IARC_TP53:28513,
IZSLER:BS TCL 237, LiGeA:CCL_132, Lonza:168, PharmacDB:MM1S_944_2019,
PRIDE:PXD021265, PRIDE:PXD030304, Progenetix:CVCL_8792,
PubChem_Cell_line:CVCL_8792, Wikidata:Q54906038

ID: CVCL_8792

Hierarchy: cvcl_5801

Record Creation Time: 20220427T220813+0000

Record Last Update: 20260913T004909+0000

Ratings and Alerts

No rating or validation information has been found for MM1.S.

No alerts have been found for MM1.S.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 261 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.

Fairfield H, et al. (2026) Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. Cancer prevention research (Philadelphia, Pa.), 19(6), 339.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(21), e18975.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 45.

Gu H, et al. (2026) FAP⁺ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(18), e06239.

Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. *Blood cancer discovery*, 7(2), 234.

Bidkar AP, et al. (2026) Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1540.

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. *STAR protocols*, 7(1), 104340.

Daly J, et al. (2026) CRISPR activation screens map the genomic landscape of cancer glycome remodeling. *Cell genomics*, 6(4), 101139.

Soemardy C, et al. (2026) Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. *ACS nano*, 20(16), 12405.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. *Cell reports*, 45(6), 117464.

Jenkins TW, et al. (2025) Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. *Scientific reports*, 15(1), 17284.

Li J, et al. (2025) Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells. *International immunopharmacology*, 148, 114113.

Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.

Rodríguez-Lobato LG, et al. (2025) Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited. *Cancer immunology research*, 13(9), 1374.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. *Cell reports. Medicine*, 6(10), 102400.

Shen N, et al. (2025) HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma. *Cell reports*, 44(5), 115720.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. *Med (New York, N.Y.)*, 100804.

Tazuru K, et al. (2025) The IAP antagonist tolinapant enhances the anti-tumor activity of cell therapies. *European journal of pharmacology*, 995, 177400.